Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...

Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

Danganronpa 2×2 is the upcoming remake of Super Danganronpa 2, which originally came out in 2012 for the PSP. While the remake will feature the original cast and characters, it’ll also include a new ...

Imbruvica is a prescription drug used in adults with chronic lymphocytic leukemia (CLL), a type of cancer that starts in the bone marrow. The drug is available in three oral forms: a capsule, tablet, ...

As a diehard enthusiast of video games, Ediz Guner has been attentively following the ebbs and flows of the gaming industry for a long period of time. This, coupled with his hobby of extensively ...

Danganronpa 2: Goodbye Despair is making a comeback in the form of Danganronpa 2x2 for PC via Steam, Nintendo Switch, Switch 2, PlayStation 5, and Xbox Series X and S. Spike Chunsoft announced a ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

In a study of patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (CLL/SLL) who do not have 17p deletions, Jaypirca topped the chemoimmunotherapy combination ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...